Zeng et al. proposed that sigma-2 selective compounds with cytotoxic effects on cancer cells are categorized as agonists, since siramesine, a commonly accepted sigma-2 agonist, induces cytotoxicity in cancer cells [29]. The gene discussed is AP2S1; the disease is cancer.